ES2277597T3 - Agentes antitromboticos. - Google Patents

Agentes antitromboticos. Download PDF

Info

Publication number
ES2277597T3
ES2277597T3 ES00968710T ES00968710T ES2277597T3 ES 2277597 T3 ES2277597 T3 ES 2277597T3 ES 00968710 T ES00968710 T ES 00968710T ES 00968710 T ES00968710 T ES 00968710T ES 2277597 T3 ES2277597 T3 ES 2277597T3
Authority
ES
Spain
Prior art keywords
baselineskip
seq
antibody
factor
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00968710T
Other languages
English (en)
Spanish (es)
Inventor
Frank C. Barone
Michael N. Blackburn
Giora Z. Feuerstein
John R. Toomey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of ES2277597T3 publication Critical patent/ES2277597T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES00968710T 2000-05-15 2000-10-05 Agentes antitromboticos. Expired - Lifetime ES2277597T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57143400A 2000-05-15 2000-05-15
US571434 2000-05-15

Publications (1)

Publication Number Publication Date
ES2277597T3 true ES2277597T3 (es) 2007-07-16

Family

ID=24283688

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00968710T Expired - Lifetime ES2277597T3 (es) 2000-05-15 2000-10-05 Agentes antitromboticos.

Country Status (20)

Country Link
US (1) US20050037006A1 (enExample)
EP (2) EP1825864A3 (enExample)
JP (1) JP2004516236A (enExample)
KR (2) KR20030034071A (enExample)
CN (2) CN101134107A (enExample)
AT (1) ATE345816T1 (enExample)
AU (2) AU7858400A (enExample)
BR (1) BR0015872A (enExample)
CA (1) CA2411369A1 (enExample)
CZ (1) CZ20023778A3 (enExample)
DE (1) DE60032029T2 (enExample)
ES (1) ES2277597T3 (enExample)
HU (1) HU225874B1 (enExample)
IL (1) IL152831A0 (enExample)
MX (1) MXPA02011385A (enExample)
NO (1) NO20025463L (enExample)
NZ (1) NZ522632A (enExample)
PL (1) PL360060A1 (enExample)
WO (1) WO2001087339A1 (enExample)
ZA (1) ZA200209265B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2807274T3 (es) 2002-03-20 2021-02-22 Univ Maryland Un canal catiónico no selectivo en células neurales y compuestos que bloquean el canal para su uso en el tratamiento de la inflamación del cerebro
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US10583094B2 (en) 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
JP5085326B2 (ja) 2004-09-18 2012-11-28 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法
WO2008089103A2 (en) 2007-01-12 2008-07-24 University Of Maryland, Baltimore Targeting ncca-atp channel for organ protection following ischemic episode
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
CA2705851C (en) * 2007-11-21 2016-11-01 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
CN118320078A (zh) * 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
US20200109390A1 (en) 2017-04-27 2020-04-09 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
US20240018503A1 (en) * 2017-04-27 2024-01-18 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体
CN121758622B (zh) * 2026-03-04 2026-07-24 上海快序生物科技有限公司 一种完全人源的抗人凝血因子ix单克隆抗体或其抗原结合片段及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
ES2177316T3 (es) * 1998-08-28 2002-12-01 Genentech Inc Anticuerpos humanos antifacotores ix/ixa.

Also Published As

Publication number Publication date
PL360060A1 (en) 2004-09-06
CN1501812A (zh) 2004-06-02
HUP0301804A2 (hu) 2003-08-28
KR20070116192A (ko) 2007-12-06
CN101134107A (zh) 2008-03-05
AU2000278584B2 (en) 2006-11-16
IL152831A0 (en) 2003-06-24
HU225874B1 (en) 2007-11-28
EP1282444B1 (en) 2006-11-22
DE60032029T2 (de) 2007-05-31
JP2004516236A (ja) 2004-06-03
HUP0301804A3 (en) 2005-12-28
BR0015872A (pt) 2004-08-03
CN100339132C (zh) 2007-09-26
MXPA02011385A (es) 2004-01-26
CZ20023778A3 (cs) 2003-08-13
EP1282444A4 (en) 2004-06-30
EP1825864A3 (en) 2007-09-12
EP1825864A2 (en) 2007-08-29
NO20025463D0 (no) 2002-11-14
NO20025463L (no) 2003-01-09
AU7858400A (en) 2001-11-26
CA2411369A1 (en) 2001-11-22
KR20030034071A (ko) 2003-05-01
WO2001087339A1 (en) 2001-11-22
ATE345816T1 (de) 2006-12-15
EP1282444A1 (en) 2003-02-12
DE60032029D1 (de) 2007-01-04
ZA200209265B (en) 2003-10-22
NZ522632A (en) 2005-05-27
US20050037006A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
ES2267131T3 (es) Anticuerpos anticoagulantes humanizados contra el factor ix, para uso en el tratamiento de la trombosis.
ES2320665T3 (es) Anticuerpos especificos del factor ixa que presentan una actividad analoga a la del factor viiia.
ES2844189T3 (es) Tratamiento y prevención de lesiones remotas por isquemia-reperfusión
AU2014301041A1 (en) Combination therapy using a Factor XII inhibitor and a C1-Inhibitor
ES2283308T3 (es) Anticuerpo monoclonal para el factor viii, que incluso cuando esta presente en exceso molar inactiva el factor viii solo en parte y metodo para producir dicho anticuerpo.
KR20040045478A (ko) 인간 조직인자 항체
EP1282444B1 (en) Antithrombotic agents
AU2000278584A1 (en) Antithrombotic agents
US20040146511A1 (en) Antithrombotic agents
US20060057140A1 (en) Anticoagulant agents useful in treatment of thrombosis
US20070190059A1 (en) Antithrombotic agents
HK1109339A (en) Antithrombotic agents
HK1107932A (en) Anticoagulant agents useful in treatment of thrombosis
HK1029513B (en) Anticoagulant humanised antibodies against factor ix, for use in the treatment of thrombosis